# EDGAR Filing Document

**Accession Number:** 0001861123
**File Stem:** 0001193125-26-037993
**Filing Date:** 2026-2
**Character Count:** 17665
**Document Hash:** 72a6c6a997ca8e7f3efd32d29dd13857
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-037993.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0001193125-26-037993

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20260204

**DATE AS OF CHANGE**: 20260204

**EFFECTIVENESS DATE**: 20260204

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eikon Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001861123
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842807586
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293213
- **FILM NUMBER:** 26599858

**BUSINESS ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030
- **BUSINESS PHONE:** 341-777-0566

**MAIL ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030

**As filed with the Securities and Exchange Commission on February 4, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-1** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## EIKON THERAPEUTICS, INC.
**(Exact Name of Registrant as Specified in Its Charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **2836** | **84-2807586** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Primary Standard Industrial**<br> **Classification Code Number)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**230 Harriet Tubman Way** 

**Millbrae, California 94030** 

**(341) 777-0566** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Roger M. Perlmutter, M.D., Ph.D.** 

**Chief Executive Officer** 

**Eikon Therapeutics, Inc.** 

**230 Harriet Tubman Way** 

**Millbrae, California 94030** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | | |
|:---|:---|:---|
| **Brian K. Rosenzweig**<br> **Bradley Chernin**<br> **Brianna M. Bloodgood**<br> **Covington & Burling LLP**<br> **30 Hudson Yards**<br> **New York, New York 10001**<br> **(212) 841-1000** | **Benjamin Thorner**<br> **Chief Business Officer and General**<br> **Counsel**<br> **Eikon Therapeutics, Inc.**<br> **230 Harriet Tubman Way**<br> **Millbrae, California 94030**<br> **(341) 777-0566** | **Alan F. Denenberg**<br> **Emily Roberts**<br> **Davis Polk & Wardwell LLP**<br> **900 Middlefield Road**<br> **Redwood City, California 94063**<br> **(650) 752-2000** |

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after this registration statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-292633

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**This registration statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.**

------

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE** 

This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"), for the sole purpose of increasing the aggregate number of shares of common stock offered by Eikon Therapeutics, Inc. (the "Registrant") by 4,059,040 shares, 529,440 of which are subject to purchase upon exercise of the underwriters' option to purchase additional shares of the Registrant's common stock. The contents of the Registration Statement on Form S-1, as amended (File No. 333-292633), including all exhibits thereto (the "Prior Registration Statement"), filed by the Registrant with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act and declared effective by the Commission on January 30, 2026, are incorporated by reference into this Registration Statement. The additional shares of common stock that are being registered for issuance and sale pursuant to this Registration Statement are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the filing fee table filed as Exhibit 107 of the Prior Registration Statement.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 5.1 | [Opinion of Covington & Burling LLP.](d26375dex51.htm) |
| 23.1 | [Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of Eikon Therapeutics, Inc.](d26375dex231.htm) |
| 23.2 | [Consent of Covington & Burling LLP (included in Exhibit 5.1 to this Registration Statement).](d26375dex51.htm) |
| 24.1 | [Power of Attorney (incorporated by reference to Exhibit 24.1 to the Prior Registration Statement).](http://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262ds1.htm#sig) |
| 107 | [Filing Fee Table.](d26375dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Millbrae, California, on the 4th day of February, 2026.

---

| | |
|:---|:---|
| **Eikon Therapeutics, Inc.** | **Eikon Therapeutics, Inc.** |
| By: | /s/ Roger M. Perlmutter, M.D., Ph.D. |
|  | Name: Roger M. Perlmutter, M.D., Ph.D. |
|  | Title: Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Roger M. Perlmutter, M.D., Ph.D. | Chief Executive Officer, Chair and Director | February 4, 2026 |
| Roger M. Perlmutter, M.D., Ph.D. | (Principal Executive Officer) |  |
| /s/ Alfred Bowie, Ph.D. | Chief Financial Officer | February 4, 2026 |
| Alfred Bowie, Ph.D. | (Principal Financial and Accounting Officer) |  |
| \* | Director | February 4, 2026 |
| Leon Chen, Ph.D. |  |  |
| \* | Director | February 4, 2026 |
| Kenneth C. Frazier |  |  |
| \* | Director | February 4, 2026 |
| Robert Huffines |  |  |
| \* | Director | February 4, 2026 |
| David Meline |  |  |
| \* | Director | February 4, 2026 |
| Joshua Wolfe |  |  |

---

---

| | |
|:---|:---|
| \*By: | /s/ Roger M. Perlmutter, M.D., Ph.D. |
|  | Roger M. Perlmutter, M.D., Ph.D. |
|  | Attorney-in-Fact |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g26375g0204115009553.jpg) | ![LOGO](g26375g0204115009774.jpg) |

---

February 4, 2026

Eikon Therapeutics, Inc.

230 Harriet Tubman Way

Millbrae, California 94030

Ladies and Gentlemen:

We have acted as counsel to Eikon Therapeutics, Inc., a Delaware corporation (the "*Company*"), and are rendering this opinion in connection with the registration by the Company under the Securities Act of 1933 (the "*Securities Act*") of the offer and sale of up to $73,062,720 in aggregate amount of shares of the Company's common stock (the "*Common Stock*"), par value $0.0001 per share (the "*Shares*"), pursuant to the registration statement on Form S-1 filed with the United States Securities and Exchange Commission on February 4, 2026, pursuant to Rule 462(b) under the Securities Act (the "*Registration Statement*"). The Registration Statement incorporates by reference the registration statement on Form S-1 (File No. 333-292633) (the "*Prior Registration Statement*"), including the prospectus that is part of the Prior Registration Statement (the "*Prospectus*").

We have reviewed:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the Prior Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Form of Underwriting Agreement (the "*Underwriting Agreement*"), to be entered into by and among the Company and J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) the Company's Amended and Restated Certificate of Incorporation, as amended, as currently in effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) the Company's Amended and Restated Bylaws, as currently in effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) Form of the Company's Amended and Restated Certificate of Incorporation, to be effective immediately prior to the closing of the offering contemplated by the Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) Form of the Company's Amended and Restated Bylaws, to be effective immediately prior to the closing of the offering contemplated by the Registration Statement.

------

![LOGO](g26375g0204115009321.jpg)

We have also reviewed such corporate records, certificates and other documents, and such questions of law, as we have deemed necessary or appropriate for the purposes of this opinion.

We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals. We have also assumed that the Shares will be duly registered on the books of the transfer agent and registrar of the Common Stock and that the Company will comply with applicable notice requirements regarding uncertificated shares provided under the Delaware General Corporation Law (the "*DGCL*"). We have assumed further that, except as to legal conclusions expressly set forth in this opinion, the information and representations and warranties contained in the agreements, instruments, records, certificates and other documents we reviewed were true, accurate and complete as of their stated date and are true, accurate and complete as of the date of this letter.

We have relied as to certain matters on information obtained from public officials, officers of the Company, and other sources believed by us to be responsible.

Based upon the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Registration Statement has become effective under the Securities Act, the Shares, when duly issued and sold as contemplated by the Underwriting Agreement, will be validly issued, fully paid and non-assessable.

We are members of the bar of the State of New York. We do not express any opinion herein on any laws other than the law of the State of New York and the DGCL.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. We also hereby consent to the reference to our firm under the heading "Legal Matters" in the Prospectus constituting part of the Prior Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

Very truly yours,<br>/s/ Covington & Burling LLP<br>

## Exhibit 23.1

**Exhibit 23.1** 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated May 9, 2025, except for the effects of the reverse stock split discussed in Note 2 to the financial statements, as to which the date is January 28, 2026, relating to the financial statements, which appears in Amendment No. 1 to the Registration Statement on Form S-1 (No. 333-292633) of Eikon Therapeutics, Inc. We also consent to the reference to us under the heading "Experts" in Amendment No. 1 to the Registration Statement on Form S-1 (No. 333-292633) incorporated by reference in this Registration Statement.

/s/ PricewaterhouseCoopers LLP

San Jose, California

February 4, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-1**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Eikon Therapeutics, Inc.**  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Security Type**  | **Security Class Title**  | **Fee Calculation or Carry Forward Rule**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Common Stock, par value $0.0001 per share | 457(o) | $73062720.00 | 0.0001381 | $10089.96 |
| Fees Previously Paid |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | $73062720.00  |  | $10089.96  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  |  |  | $10089.96  |

---

 **Offering Note** <br>

<sup>1</sup> Represents only the additional $73,062,720 of shares of common stock being registered pursuant to this registration statement and includes shares of common stock that the underwriters have the option to purchase. Does not include the $365,313,600 of shares of common stock that were previously registered on the Registration Statement on Form S-1 (File No. 333-292633), as amended (the "Prior Registration Statement"). (2) Based on the public offering price. (3) The registration fee is calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act"), based on the maximum aggregate offering price. The registrant previously registered an aggregate of $365,313,600 of shares of its common stock on the Prior Registration Statement, which was declared effective by the Securities and Exchange Commission on January 30, 2026. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a maximum aggregate offering price of $73,062,720 is hereby registered, which includes shares of common stock that the underwriters have the option to purchase.

---

| | |
|:---|:---|
| | |
| **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Amount of Securities Previously Registered**  | **Maximum Aggregate Offering Price of Securities Previously Registered**  | **Form Type**  | **File Number**  | **Initial Effective Date**  |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

---